SLA

Across TCGA pan-cancer cohorts, SLA Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLA data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SLA Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SLA expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

UCEC, DLBC, and LUSC are the cancer types where SLA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.621	.002	36	view →
DLBC	OS	Median	III,IV	0.172	0.907	<.001	12	view →
LUSC	OS	Median	All	0.156	0.659	.018	12	view →
LUAD	OS	Median	All	0.284	0.673	.033	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
COAD	DFS	Median	IV	1.000	0.266	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLA–UCEC (DFS)

Open the UCEC breakdown →